ACTA1 and chronic obstructive pulmonary disease: Compared with the model group, the COPD model rats treated with RRL could inhibit the expression of NF-κB p65, p-IκBα, TGF-β1, and α-SMA together with upregulation of Nrf2 and HO-1(Figure 14).